Fluorescence PCR · Febrile Encephalitis
Bundibugyo Ebola Virus Nucleic Acid Detection Kit (Fluorescence PCR)
This kit is intended for the in vitro qualitative detection of Bundibugyo ebolavirus (BDBV) nucleic acid in human whole blood, serum/plasma, and oral swab samples. It aids in diagnosis of BDBV infection, which causes viral hemorrhagic fever and cannot be distinguished from other Ebola viruses by clinical symptoms alone.
- SKU Code
AENE-FE4023- Approval
- On request
- Product Type
- Assay / Kit
- Status
- Available
This kit is intended for the in vitro qualitative detection of Bundibugyo ebolavirus (BDBV) nucleic acid in human whole blood, serum/plasma, and oral swab samples. It aids in diagnosis of BDBV infection, which causes viral hemorrhagic fever and cannot be distinguished from other Ebola viruses by clinical symptoms alone.
| Product type | Assay / Kit |
|---|---|
| Technology platform | Fluorescence PCR |
| Application area | Febrile Encephalitis |
Epidemiology
Belonging to the family Filoviridae, this virus is the third ebolavirus known to cause large-scale human outbreaks, after Zaire ebolavirus (EBOV) and Sudan ebolavirus (SUDV). Bundibugyo ebolavirus (BDBV) possesses a single-stranded, negative-sense RNA genome of roughly 19 kb, coding for 7 structural and 2 non-structural proteins. The incubation period ranges from 2 to 21 days, averaging 6.3 days. Clinical signs closely resemble those of other Ebola viruses, making differential diagnosis based on symptoms alone impossible. The virus was first recognized during an unexplained hemorrhagic fever outbreak in Uganda’s Bundibugyo District in August 2007, where it was identified as a novel species and named Bundibugyo ebolavirus (BDBV). That outbreak involved 93 suspected cases, 56 confirmed infections, and 37 fatalities (case fatality rate: 25%). A subsequent outbreak occurred in 2012 in the Orientale Province of the Democratic Republic of the Congo, resulting in 38 confirmed cases and 13 deaths (case fatality rate: 34%). In May 2026, the WHO designated the ongoing BDBV outbreak in the Democratic Republic of the Congo and Uganda as a Public Health Emergency of International Concern (PHEIC). By May 20, there were 246 suspected cases and 80 deaths.
Work flow
The workflow accommodates two protocol types: Type I and Type II. The following self-prepared items are required:
- Self-prepared Reagents: physiological saline, nucleic acid extraction reagents
- Self-prepared Consumables: DNase/RNase-free pipette tips, disposable gloves, 1.5 mL DNase/RNase-free centrifuge tubes, centrifuge
| SKU code | AENE-FE4023 |
|---|---|
| Storage | ≤-18℃ |
| Shelf-life | 12 months |
| Specimen Type | whole blood, serum/plasma, o ral swab |
| Ct | ≤38 |
| CV | ≤5.0% |
| LoD | 3 00 Copies/mL |
| Applicable Instruments | Type I: ABI 7500/7500 Fast Real-Time PCR System, QuantStudio®5 Real-Time PCR System, QuantStudio®7 Real-Time PCR System, Hongshi SLAN-96P/S Fully Automatic Medical PCR Analysis System, LightCycler®480 Real-Time PCR System, Hangzhou Bioer FQD-96A Real-Time PCR System, Yarui MA-6000 Real-Time PCR System, BioRad CFX96 Real-Time PCR System, BioRad CFX Opus 96 Real-Time PCR System. Type II: -Automatic Molecular Detection System |
| Approval | On request |
|---|---|
| Documents | Datasheet, IFU, SDS, COA / conformance, origin, and export documents where available |
FAQ
What should be confirmed before quotation?
Sample context, collection method, and extraction workflow should be confirmed before final kit selection.
Which documents can be requested?
Datasheet, IFU, SDS, COA / conformance, origin, insurance, and export documents can be checked where available.
Can the format be adjusted for different workflows?
Liquid or lyophilized format options should be confirmed together with instrument compatibility and shipment requirements.
Inquiry
Send the essentials for a useful first reply.
Share the application, sample type, format, destination, and expected quantity so AeneBio can route AENE-FE4023 to the right quote or sample discussion.